Literature DB >> 25027326

Heterozygous deletion of the Williams-Beuren syndrome critical interval in mice recapitulates most features of the human disorder.

Maria Segura-Puimedon1, Ignasi Sahún2, Emilie Velot3, Pierre Dubus4, Cristina Borralleras5, Ana J Rodrigues6, María C Valero7, Olga Valverde8, Nuno Sousa6, Yann Herault3, Mara Dierssen9, Luis A Pérez-Jurado10, Victoria Campuzano11.   

Abstract

Williams-Beuren syndrome is a developmental multisystemic disorder caused by a recurrent 1.55-1.83 Mb heterozygous deletion on human chromosome band 7q11.23. Through chromosomal engineering with the cre-loxP system, we have generated mice with an almost complete deletion (CD) of the conserved syntenic region on chromosome 5G2. Heterozygous CD mice were viable, fertile and had a normal lifespan, while homozygotes were early embryonic lethal. Transcript levels of most deleted genes were reduced 50% in several tissues, consistent with gene dosage. Heterozygous mutant mice showed postnatal growth delay with reduced body weight and craniofacial abnormalities such as small mandible. The cardiovascular phenotype was only manifested with borderline hypertension, mildly increased arterial wall thickness and cardiac hypertrophy. The neurobehavioral phenotype revealed impairments in motor coordination, increased startle response to acoustic stimuli and hypersociability. Mutant mice showed a general reduction in brain weight. Cellular and histological abnormalities were present in the amygdala, cortex and hippocampus, including increased proportion of immature neurons. In summary, these mice recapitulate most crucial phenotypes of the human disorder, provide novel insights into the pathophysiological mechanisms of the disease such as the neural substrates of the behavioral manifestations, and will be valuable to evaluate novel therapeutic approaches.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2014        PMID: 25027326     DOI: 10.1093/hmg/ddu368

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  28 in total

Review 1.  Critical reappraisal of mechanistic links of copy number variants to dimensional constructs of neuropsychiatric disorders in mouse models.

Authors:  Noboru Hiroi
Journal:  Psychiatry Clin Neurosci       Date:  2018-03-01       Impact factor: 5.188

2.  Functions of Gtf2i and Gtf2ird1 in the developing brain: transcription, DNA binding and long-term behavioral consequences.

Authors:  Nathan D Kopp; Kayla R Nygaard; Yating Liu; Katherine B McCullough; Susan E Maloney; Harrison W Gabel; Joseph D Dougherty
Journal:  Hum Mol Genet       Date:  2020-06-03       Impact factor: 6.150

3.  Gtf2i and Gtf2ird1 mutation do not account for the full phenotypic effect of the Williams syndrome critical region in mouse models.

Authors:  Nathan Kopp; Katherine McCullough; Susan E Maloney; Joseph D Dougherty
Journal:  Hum Mol Genet       Date:  2019-10-15       Impact factor: 6.150

4.  Symmetrical Dose-Dependent DNA-Methylation Profiles in Children with Deletion or Duplication of 7q11.23.

Authors:  Emma Strong; Darci T Butcher; Rajat Singhania; Carolyn B Mervis; Colleen A Morris; Daniel De Carvalho; Rosanna Weksberg; Lucy R Osborne
Journal:  Am J Hum Genet       Date:  2015-07-09       Impact factor: 11.025

5.  Identification of a transcriptional signature found in multiple models of ASD and related disorders.

Authors:  Samuel Thudium; Katherine Palozola; Éloïse L'Her; Erica Korb
Journal:  Genome Res       Date:  2022-09-14       Impact factor: 9.438

6.  Intracisternal Gtf2i Gene Therapy Ameliorates Deficits in Cognition and Synaptic Plasticity of a Mouse Model of Williams-Beuren Syndrome.

Authors:  Cristina Borralleras; Ignasi Sahun; Luis A Pérez-Jurado; Victoria Campuzano
Journal:  Mol Ther       Date:  2015-07-28       Impact factor: 11.454

7.  Whole exome sequencing in patients with Williams-Beuren syndrome followed by disease modeling in mice points to four novel pathways that may modify stenosis risk.

Authors:  Phoebe C R Parrish; Delong Liu; Russell H Knutsen; Charles J Billington; Robert P Mecham; Yi-Ping Fu; Beth A Kozel
Journal:  Hum Mol Genet       Date:  2020-07-29       Impact factor: 6.150

8.  Oxytocin receptor activation does not mediate associative fear deficits in a Williams Syndrome model.

Authors:  Kayla R Nygaard; Raylynn G Swift; Rebecca M Glick; Rachael E Wagner; Susan E Maloney; Georgianna G Gould; Joseph D Dougherty
Journal:  Genes Brain Behav       Date:  2021-06-10       Impact factor: 3.449

Review 9.  Oxidative Stress in Down and Williams-Beuren Syndromes: An Overview.

Authors:  Marta Ferrari; Stefano Stagi
Journal:  Molecules       Date:  2021-05-24       Impact factor: 4.411

Review 10.  Williams syndrome.

Authors:  Beth A Kozel; Boaz Barak; Chong Ae Kim; Carolyn B Mervis; Lucy R Osborne; Melanie Porter; Barbara R Pober
Journal:  Nat Rev Dis Primers       Date:  2021-06-17       Impact factor: 65.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.